PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL
Thomas Menter(University of Basel), S Dirnhofer(University Hospital of Basel), Felicitas Hitz(Kantonsspital St. Gallen), Peter de Nully Brown(Copenhagen University Hospital), Hans Hagberg(Uppsala University Hospital), Alexandar Tzankov(University of Basel), Hanne Hawle(Swiss Group For Clinical Cancer Research), Ulrich Mey(Kantonsspital Graubünden), Stefanie Hayoz(Swiss Group For Clinical Cancer Research), M. Hernberg(Helsinki University Hospital), Eva Kimby(Karolinska University Hospital), Björn E. Wahlin(Karolinska University Hospital), Bjørn Østenstad(Oslo University Hospital), Emanuele Zucca(Università della Svizzera italiana), Anna Vanazzi(European Institute of Oncology), Ann‐Sofie Johansson(University Hospital of Umeå), Daniel Rauch(Washington University in St. Louis)
Cited by 1
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568